Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
TP53 P53
Sequence Length (AA) Molecular Weight (Da)
393 43653
Protein Name
Cellular tumor antigen p53
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI
60 70 80 90 100
EQWFTEDPGP DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ
110 120 130 140 150
KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT CPVQLWVDST
160 170 180 190 200
PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN
210 220 230 240 250
LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP
260 270 280 290 300
ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
310 320 330 340 350
PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL
360 370 380 390 393
KDAQAGKEPG GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-951 Collapse assay details

Data source: Panorama

Official Gene Symbol
TP53
Peptide Modified Sequence
ALPNNTSSS[+80.0]PQPK
Modification Type
Phospho (ST)
Protein - Site of Modification
315
Peptide - Site of Modification
9
Peptide Start
307
Peptide End
319
CPTAC ID
CPTAC-951
Peptide Molecular Mass
1,419.6395
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
cell lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Kennedy JJ, Yan P, Zhao L, Ivey RG, Voytovich U, Moore HD, Lin C, Pogosova-Agadjanyan EL, Stirewalt DL, Reding KW, Whiteaker JR, Paulovich AG. Immobilized metal affinity chromatography coupled to multiple reaction monitoring enables reproducible quantification of phospho-signaling. Molecular and Cellular Proteomics. mcp.O115.054940


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
QTrap 5500 (Sciex)
Internal Standard
Peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
nanoLC-2D (Eksigent)
Column Packing
ChromXP C18-CL, 3 µm, 120 Å
Column Dimensions
75 µm x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b8 (1+) 63.8 71.1 45.7 60.3 78.3 101.2 87.8 105.8 111 15 24 15
y10 (2+) 15.7 12.4 10 33.5 14.3 14 37 18.9 17.2 15 24 15
y11 (2+) 12.9 11.7 6.8 24.4 11.3 7.8 27.6 16.3 10.3 15 24 15
y5 (1+) 49.6 35.7 34.7 61.6 33 42.3 79.1 48.6 54.7 15 24 15
y7 (1+) 22.5 13.1 10.9 23.6 14.4 11.5 32.6 19.5 15.8 15 24 15
sum 12.3 11.6 7.1 23.5 11.1 7.9 26.5 16.1 10.6 15 24 15


Additional Resources and Comments


Assay Details for CPTAC-5896 Collapse assay details

Data source: Panorama

Official Gene Symbol
TP53
Peptide Modified Sequence
ALPNNTSSS[+79.966331]PQPK
Modification Type
Phospho (ST)
Protein - Site of Modification
316
Peptide - Site of Modification
9
Peptide Start
307
Peptide End
319
CPTAC ID
CPTAC-5896
Peptide Molecular Mass
1,419.6395
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y9 (1+) 141.6 41.6 26.2 173.2 54.1 29.7 223.7 68.2 39.6 15 27 15
y7 (1+) 101.9 49.6 36.9 123.4 71.9 38.6 160 87.3 53.4 15 27 15
y4 (1+) 61.3 33.3 13.6 65.4 32.6 18.5 89.6 46.6 23 15 27 15
y11 (2+) 21.4 11.8 9.1 33.5 14.6 11.9 39.8 18.8 15 15 27 15
y10 (2+) 83.4 43.1 27.8 142.6 47.8 23.7 165.2 64.4 36.5 15 27 15
y11 (1+) 81.6 37.1 22.1 121.3 45.2 24.5 146.2 58.5 33 15 27 15
sum 15.1 10.2 7.9 22.7 13 10.7 27.3 16.5 13.3 15 27 15


Additional Resources and Comments


Assay Details for CPTAC-5895 Collapse assay details

Data source: Panorama

Official Gene Symbol
TP53
Peptide Modified Sequence
MEEPQSDPSVEPPLS[+79.966331]QETFSDLWK
Modification Type
Phospho (ST)
Protein - Site of Modification
16
Peptide - Site of Modification
15
Peptide Start
1
Peptide End
24
CPTAC ID
CPTAC-5895
Peptide Molecular Mass
2,855.2249
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b7 (1+) 51.2 20.8 22.4 53.8 24.5 34.3 74.3 32.1 41 15 27 15
y12 (2+) 57 24.2 19.4 63.5 30.3 20.9 85.3 38.8 28.5 15 27 15
y13 (2+) 38.8 8.7 4.9 41.9 21.1 13.7 57.1 22.8 14.5 15 27 15
y17 (2+) 42.6 18.7 17.4 60.2 29 18.3 73.7 34.5 25.3 15 27 15
y5 (1+) 30.3 41.5 36.3 43.2 42.7 57.6 52.8 59.5 68.1 15 27 15
y10-98 (1+) 67.6 68.3 51.3 69.4 114.1 86.9 96.9 133 100.9 13 26 14
b14 (2+) 59.9 98.3 31.8 99 91.8 94.4 115.7 134.5 99.6 14 23 14
b11 (1+) 41 21.4 9 52.7 27.6 20.4 66.8 34.9 22.3 15 27 15
b10 (1+) 23.1 23.5 9.3 31.5 31.1 19.7 39.1 39 21.8 15 27 15
y13-98 (2+) 43.7 26 7.4 49 30.2 19.4 65.7 39.9 20.8 15 27 15
sum 18.1 8.1 1.8 29.9 19.9 15 35 21.5 15.1 15 27 15


Additional Resources and Comments